Skip to main content
Chengdu Kanghong Pharmaceutical Group Co., Ltd logo

Chengdu Kanghong Pharmaceutical Group Co., Ltd — Investor Relations & Filings

Ticker · 002773 ISIN · CNE1000020C4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,502 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002773

About Chengdu Kanghong Pharmaceutical Group Co., Ltd

http://www.cnkh.com

Chengdu Kanghong Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative drugs and medical devices. The organization specializes in therapeutic areas such as ophthalmology, the central nervous system, and the digestive system. A core product is Conbercept, a recombinant fusion protein designed for treating wet age-related macular degeneration and other retinal disorders. The group maintains a diverse pipeline that includes biologics, small molecule chemicals, and modern herbal medicines. By leveraging integrated research platforms and advanced manufacturing capabilities, the company develops therapeutic solutions for chronic and age-related conditions. Its operations emphasize the transition from traditional formulations to high-tech biological innovations, supported by a comprehensive clinical development and distribution infrastructure.

Recent filings

Filing Released Lang Actions
北京通商（成都）律师事务所关于成都康弘药业集团股份有限公司二〇二五年度股东会之法律意见书
Regulatory Filings Classification · 87% confidence The document is a legal opinion letter (“法律意见书”) issued by a law firm on the legality of convening and holding Chengdu Kanghong Pharmaceutical Group Co., Ltd.’s 2025 annual shareholders’ meeting. It is not the meeting notice or pure voting results announcement, nor is it financial data or a management report. It is primarily an attestation/certification by lawyers confirming legal compliance. Under the “CERTIFICATION RULE,” such legal opinion/attestation letters are classified as Regulatory Filings (RNS) when no other more specific category applies.
2026-05-21 Chinese
关于举行二〇二五年度网上业绩说明会的公告
Investor Presentation Classification · 90% confidence The document is an announcement about holding an online earnings presentation (业绩说明会) for the fiscal year 2025. It references that the 2025 Annual Report has already been disclosed on April 23, 2026, and invites investors to participate in the online earnings explanation meeting scheduled for May 11, 2026. The document does not contain actual financial data or detailed financial statements but serves as a notice for an upcoming investor presentation event. According to the classification rules, such announcements about presentations or meetings are classified as Investor Presentation (IP). The document length is short and it is clearly an announcement for a presentation rather than the presentation itself, but given the nature of the event (earnings explanation meeting), the best fit is Investor Presentation (IP).
2026-05-06 Chinese
2026年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '成都康弘药业集团股份有限公司2026年第一季度报告' (Chengdu Kanghong Pharmaceutical Group Co., Ltd. 2026 First Quarter Report). It contains comprehensive financial statements, including the balance sheet, income statement, and cash flow statement for the first quarter of 2026. It is not an announcement of a report, but the report itself, and it contains substantive financial data. Therefore, it is classified as an Interim/Quarterly Report. Q1 2026
2026-04-22 Chinese
董事会审计委员会对会计师事务所2025年度履行监督职责情况的报告
Audit Report / Information Classification · 85% confidence The document is a Board Audit Committee’s report on the external auditor’s performance in supervising the company’s 2025 audit. It is not the full annual report (10-K/IR), nor an earnings release or management discussion, but rather a standalone audit-related disclosure. This matches the definition of Audit Report / Information (Code: AR). FY 2025
2026-04-22 Chinese
成都康弘药业集团股份有限公司2025年度非经营性资金占用及其他关联资金往来的专项说明
Regulatory Filings Classification · 85% confidence The document is a "专项说明" (special explanatory note) for non-operating fund occupations and other related‐party fund transactions for the 2025 fiscal year, prepared under CSRC Listing Regulation No.8 and Shenzhen Exchange disclosure rules. It is not the full Annual Report (10-K), not the standalone audit report (AR), nor any earnings release, presentation or other specific category. It is a regulatory‐mandated supplemental disclosure that does not fit any more narrowly defined filing type, so it defaults to Regulatory Filings (RNS).
2026-04-22 Chinese
2025年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 95% confidence The document is a 'Summary Table of Non-Operating Fund Occupancy and Other Related Party Fund Transactions' for 2025. It provides specific financial data regarding inter-company transactions and fund movements. This type of disclosure is a standard regulatory requirement in Chinese listed company filings (often part of the annual audit or periodic reporting package). Since it contains substantive financial data and is not a mere announcement of a report, it falls under the category of regulatory filings or financial disclosures. Given the specific nature of the table, 'RNS' (Regulatory Filings) is the most appropriate classification as it serves as a compliance document. FY 2025
2026-04-22 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.